In the cohort 3 from the ZUMA-1 trial, patients that received tocilizumab early during application of 19
In the cohort 3 from the ZUMA-1 trial, patients that received tocilizumab early during application of 19.28.z CAR T cells had a lower life expectancy incidence of quality 3 CRS, but an increased price of all-grade neurotoxicity.22 However, the last mentioned may be from the particular focus on antigen closely, since neurotoxicity is nearly absent…
Read more